Core Insights - H&H International Investment, managed by investor Duan Yongping, has made significant adjustments to its portfolio in Q4 2025, notably reducing its stake in Apple while increasing investments in AI-related stocks [1][2]. Portfolio Adjustments - In Q4 2025, Duan Yongping reduced his holdings in several stocks, including Apple (AAPL) by 10.12%, Occidental Petroleum (OXY) by 1.27%, Alibaba (BABA) by 1.24%, ASML Holding (ASML) by 0.47%, and Walt Disney (DIS) by 0.1% [2]. - Despite the reduction, Apple remains the largest holding in Duan's portfolio, with a market value of $8.797 billion, accounting for 50.3% of the total portfolio, although he sold 2.4706 million shares [3]. Investment in AI - Duan Yongping significantly increased his position in NVIDIA, acquiring 6.6393 million shares, marking a 1110.62% increase, with a total market value of $1.35 billion, making it the third-largest holding at 7.72% of the portfolio [3]. - Additionally, Duan initiated positions in three AI-related companies: CoreWeave (299,900 shares), Credo (141,300 shares), and Tempus (110,000 shares), targeting key areas in the AI supply chain [3]. Strategic Outlook - In early January, Duan expressed a strong interest in learning about AI, indicating a belief that the technology will significantly transform the world in the coming years, potentially more than in the past decades [3].

华见早安之声 请各位听众升级为见闻最新版APP，以便成功收听以下音频。 市场概述 科技股力撑美股两连阳，美联储会议纪要显露巨大分歧，一些官员暗示加息可能，美股盘中显著较日高回落，美债跌。 道指一度闪跌。英伟达涨1.6%。被Bill Ackman基金增持的亚马逊涨近2%。芯片指数收涨近1%。获对冲基金Appaloosa大幅增持的美光涨超5%。泛欧股指三 连涨，创历史新高，英股连创新高。 美伊风险助原油大反弹，原油收涨超4%、创近四个月最大涨幅，美油一度涨超5%，布油本月内首次收盘站上70美元。 美联储会议纪要后，美债收益率加速上行。美元指数创逾一周新高，日元跌幅扩大至1%，英镑再创逾三周新低，比特币跌破6.6万美元刷新日低、较日高跌 近4%。 美油大涨5%！美以或对伊朗联合袭击，白宫称谈判取得进展、但关键议题相距甚远。 特斯拉首辆Cybercab下线：没有方向盘和踏板的汽车终于来了。 谷歌抢在苹果iPhone 17e之前发布Pixel 10a，升级有限，仍卖499美元。 金银反弹，盘中黄金涨近3%、白银涨6.5%，美联储纪要后收窄涨幅，黄金失守5000美元。 要闻 美联储会议纪要暴巨大分歧：一些官员支持进一步降 ...

段永平自己说得很直白："AI的历史车轮滚滚向前，会碾碎所有AI的泡沫，但那些没完蛋的，很可能就 是下一个Google。" 所以问题来了：当"股神"和"中国巴菲特"同时用脚投票，你觉得他们是在逃离科技，还是在重新定义科 技？评论区聊聊。 一个细节值得细品：伯克希尔唯一的建仓股，是纽约时报；段永平新进的三家公司——CoreWeave、 Credo、Tempus，清一色AI产业链，从算力租赁到高速连接到AI医疗，全覆盖。 两位大佬都在减持苹果，但钱去了不同地方。巴菲特往传统媒体躲，段永平往AI赛道冲。一个求稳， 一个求变。 昨晚，两份13F文件同时炸场。 巴菲特卸任前最后一季，减持苹果超1029万股，亚马逊清仓式减持77%。段永平同步动手，减持苹果 247万股，同时加仓英伟达超11倍，直接怼到13.5亿美元，成为第三大持仓。 ...

当地时间2月17日美股盘后，伯克希尔哈撒韦公司（下简称"伯克希尔"）向美国证监会（SEC）披露了最新13F文件。13F持仓报告显示， 在巴 菲特担任CEO的最后一季度， 伯克希尔对科技股的持仓进行了大幅调整，大举减持了苹果、亚马逊。 同时，首次建仓传统媒体纽约时报。 整体来看，截至2025年四季度末，伯克希尔前十大重仓股相较前一季度并未发生变化，只是在排名上略微调整。 这十大重仓股分别是：苹 果、美国运通、美国银行、可口可乐、雪佛龙、穆迪、西方石油、瑞士安达保险、卡夫亨氏、Alphabet。 与此同时， 知名投资人段永平也在2025年第四季度减持了苹果 ，减持数量为247.06万股，减持幅度达7.09%。 虽然苹果股价已连续三年上涨，2025年涨幅约9%，但仍跑输标普500指数。年初至今，苹果表现更弱，股价已下跌2.7%，上周甚至创下自去年4月以来最 差单日表现。 纽约时报股价近期表现强劲，2026年以来上涨近7%，目前接近历史高点74.59美元，过去12个月累计涨幅达50%。伯克希尔13F文件披露后，纽 约时报美股股价在盘后交易中涨超2%。 报告还显示，伯克希尔2025年第四季度大幅增持了雪佛龙和瑞士安达保 ...

Group 1 - Berkshire Hathaway significantly reduced its holdings in Apple and Amazon in the fourth quarter of 2025, with a 77% reduction in Amazon and a sale of over 10.29 million shares of Apple, decreasing its stake from 22.69% to 22.60% [4][5][6] - The fourth quarter marked the last 13F filing under Warren Buffett's leadership, as Greg Abel officially took over as CEO on January 1, 2026 [4][6] - Despite the reductions, Apple remains Berkshire's largest holding, while Amazon's shares fell to approximately 2.3 million, representing a drastic decline in ownership [6][7] Group 2 - Notable investor Duan Yongping also reduced his Apple holdings by 247.06 million shares, a decrease of 7.09%, while significantly increasing his investment in Nvidia by 663.93 million shares, marking a 1110.62% increase [8][9] - Duan's investment strategy appears to focus on AI, as he also initiated positions in three AI-related companies: CoreWeave, Credo, and Tempus [9][10] - Duan increased his stake in Berkshire Hathaway by 198.5 million shares, a rise of 38.24%, making it his second-largest holding [9][10]

Summary of Conference Call Notes Industry Focus - The focus is on the **AI healthcare sector**, particularly the integration of artificial intelligence in medical applications and services [1][2]. Core Insights and Arguments - The **Chinese government** emphasizes the need to promote large-scale commercial applications of AI, aiming to enhance the AI industry and expand high-value application scenarios [1]. - Recent advancements include **DeepSeek's version update** and the launch of **GLM-5**, indicating continuous breakthroughs in AI models [2]. - The **AI healthcare sector** is gaining traction due to supportive policies, technological advancements, and the gradual commercialization of pathology-assisted diagnostics [2]. - Clear application scenarios for AI in healthcare have been identified: - **B-end applications**: Involvement in medical imaging, surgical robots, in vitro diagnostics, and radiotherapy. - **C-end applications**: Empowering health management, chronic disease monitoring, personalized treatment suggestions, and academic research for doctors [2]. - Continuous policy support is evident through various documents that outline development directions and commercial pathways for AI in healthcare [2]. - The **first inclusion of "AI-assisted"** in the pricing project guidelines for pathology services marks a significant step towards commercialization [2]. - National-level AI application pilot platforms are being promoted in regions like **Beijing and Zhejiang**, enhancing industry conversion efficiency [2]. Additional Important Content - The **AI application market** is experiencing a surge in interest, driven by competition among major tech companies (ByteDance, Tencent, Alibaba, Baidu) in the general AI application field [3]. - Recent achievements, such as **ByteDance's Seedance 2.0**, demonstrate a shift from mere generation capabilities to commercial viability [3]. - The performance of companies like **Tempus** supports the feasibility of AI healthcare business models [3]. - Investment recommendations include companies such as **Dian Diagnostics, KingMed Diagnostics, and Meinian Health** [4]. - Risks highlighted include potential delays in policy implementation and slow commercialization of products or services [5].

Summary of Conference Call Records Industry: AI in Healthcare Key Points and Arguments - **Government Support for AI in Healthcare** The State Council emphasized the need to promote large-scale commercial applications of AI, enhance AI terminal and service consumption, and develop AI application pilot bases. This indicates strong governmental backing for the AI healthcare sector [1] - **Technological Advancements** Recent updates in AI models, such as DeepSeek's version update and the launch of GLM-5 by Zhizhu, demonstrate continuous breakthroughs in AI technology. This progress is crucial for the development of AI applications in healthcare [1] - **Commercialization Pathways** The introduction of guidelines like the "Pathology Medical Service Pricing Project" which includes "AI-assisted" services, paves the way for commercialization in the healthcare sector. This is a significant step towards integrating AI into medical services [2] - **Regional Initiatives** Various regions, including Beijing and Zhejiang, are advancing national-level AI application pilot platforms to enhance industrial transformation efficiency. This reflects a commitment to integrating AI with technological innovation [2] - **Market Dynamics and Competition** Major tech companies such as ByteDance, Tencent, Alibaba, and Baidu are competing in the general AI application space, which is driving the proliferation and iteration of AI technologies. For instance, ByteDance's Seedance 2.0 has achieved a breakthrough from "capable of generation" to "capable of commercialization" [2] - **Performance Validation** Companies like Tempus are demonstrating the viability of AI healthcare business models through their performance, further validating the potential of AI applications in the medical field [2] Investment Recommendations - **Growth Potential in AI Healthcare** Given the clear policy support, increasing market attention, and maturing technology, the AI healthcare sector is viewed as having significant growth potential. Recommended companies to watch include Dean Diagnostics, KingMed Diagnostics, and Meinian Health [3]

Summary of Key Points Core Viewpoint - Baillie Gifford's total holdings value decreased to $120.34 billion in Q4 2025, down approximately 10.8% from $135 billion in Q3 2025, primarily due to a net selling strategy and some growth stocks experiencing high-level corrections [1][2]. Group 1: Portfolio Adjustments - Nvidia remains the largest holding despite a 5.76% reduction in shares, accounting for 6.80% of the portfolio [3]. - Mercado Libre saw a 4.95% increase in holdings, raising its share to 5.83%, solidifying its position as a cornerstone of the portfolio [3]. - The top five holdings also include Amazon, Shopify, and Sea Ltd, with the top ten holdings comprising 43.4% of the total portfolio [4]. Group 2: Notable Transactions - Significant reductions were made in Amazon, Shopify, Meta, and Cloudflare, while Google saw a notable increase in holdings by 166%, reflecting a strategic shift towards AI capabilities [5][6]. - Baillie Gifford's investment in Google is valued at approximately $1.7 billion post-increase [6]. Group 3: Investment Philosophy and Trends - The investment team emphasizes the importance of adapting to the AI wave, suggesting that companies must pivot quickly to meet new market demands [9][10][12]. - The transition to AI is viewed as a new paradigm shift, with potential for significant growth opportunities as new companies emerge [14][15]. - The focus is on both "AI core" companies and those using AI as a tool to enhance existing services [21][24]. Group 4: Insights on China and Platform Companies - The sentiment in China has shifted, with a recognition of the country's potential to foster visionary entrepreneurs, particularly in the battery sector where CATL holds a significant market share [25][26]. - Platform companies are highlighted for their ability to create value through network effects and adaptability, requiring a long-term investment perspective [28]. Group 5: Non-Public Company Investments - Baillie Gifford has committed over £6 billion to non-public companies since 2012, recognizing the increasing duration of private company ownership before IPOs [31][32]. - The firm holds significant stakes in companies like SpaceX and ByteDance, which have shown substantial revenue growth compared to public market indices [33]. Group 6: Portfolio Construction Approach - The investment strategy is bottom-up, focusing on global transformations rather than specific trends or technologies [34]. - The portfolio includes a diverse range of companies across various sectors, with ongoing adjustments to capitalize on emerging growth opportunities [38].

Core Viewpoint - The article emphasizes a "silent revolution" in the healthcare sector driven by AI, where traditional medical giants are leveraging AI to enhance operational efficiency and cash flow, moving away from the hype surrounding pure AI startups [4][5]. Group 1: Capital Shift - Smart money is rapidly withdrawing from chasing "pure AI tools" and is instead investing heavily in traditional healthcare giants like Medtronic, Intuitive Surgical, GE Healthcare, and Boston Scientific that are systematically transforming themselves with AI [4][5]. - The underlying logic of this capital shift is a complete migration of valuation paradigms, favoring tangible operational improvements over mere technological advancements [5]. Group 2: Operational Alpha - The concept of "Operational Alpha," proposed by Bessemer Venture Partners, focuses on whether AI can enable a company to perform the work of ten people more efficiently and cost-effectively [7]. - Investors are now prioritizing quantifiable financial improvements, such as reducing clinical evaluation report preparation time from 400 hours to 140 hours, which can lead to significant early cash flow [7][10]. Group 3: Efficiency Revolution - The efficiency revolution is driven by three main arteries that enhance cash flow for healthcare giants: 1. **Accelerating Value Realization**: AI can reduce the time required for clinical evaluation reports, significantly speeding up product market entry and increasing net present value [10]. 2. **Optimizing Supply Chain and Inventory**: AI-driven predictive algorithms can release $400 million to $600 million in operational cash by optimizing inventory management [11]. 3. **Enhancing Customer Lifetime Value**: AI transforms products into long-term solutions, increasing customer reliance and stabilizing cash flow [12]. Group 4: Challenges for AI Startups - Pure AI medical startups are facing a capital winter due to three major hurdles: integration challenges with complex hospital IT systems, high compliance costs associated with new regulations, and data barriers that prevent access to high-quality training data [13][15]. - Investors are now more inclined to support established companies with stable cash flows and customer networks that are effectively using AI to enhance efficiency, rather than taking risks on startups that must overcome significant technological and regulatory obstacles [15]. Group 5: M&A Trends - The 2026 M&A landscape will focus on "efficiency enhancement" rather than mere scale expansion, with acquisitions aimed at integrating companies that can directly improve operational efficiency [16]. - Notable examples include Tempus acquiring Paige for its AI cancer detection software and extensive data set, and Stryker acquiring Inari Medical for its real-time surgical data processing capabilities [16]. Group 6: Future Industry Dynamics - The narrative of "disrupting giants" is shifting towards becoming indispensable components within the efficiency arsenal of larger companies, with startups needing to demonstrate quantifiable cash return improvements to attract investment [17][19]. - Investors must shift their due diligence focus from the allure of technology to the ability of businesses to accelerate cash returns, emphasizing the importance of free cash flow trends and cash turnover days [19].

一则来自A股市场的公告震动AI与医疗投资圈——科大讯飞发布2025年全年业绩预告，预计归属于上市 公司股东的净利润同比增长40%至70%。 在宏观经济承压、科技板块估值普遍回调的背景下，这一增长不仅彰显其核心业务韧性，更释放出一个 关键信号：以AI驱动的垂直场景商业化已进入收获期。 而在科大讯飞七大战略业务板块中，医疗板块的表现尤为亮眼。作为该板块的核心载体，已在港交所独 立上市的讯飞医疗科技（02506），正凭借母公司在人工智能底层技术上的持续突破，叠加自身在中国 基层医疗体系中的深度扎根与落地沉淀，构筑起难以复制的技术护城河与市场壁垒。站在全球AI医疗 浪潮的潮头，讯飞医疗科技的价值重估时刻已然到来。 医疗板块成科大讯飞增长新引擎 科大讯飞2025年的业绩高增长，并非源于单一产品爆发，而是其"平台+场景"战略在多个赛道协同发力 的结果。其中，医疗业务作为最早实现规模化商业闭环的板块之一，已成为重要的增长贡献点。 据内部拆解，讯飞医疗2025年的市场渗透与服务能力持续跃升：核心产品智医助理已在全国超7.7万家 基层医疗机构完成部署；智慧医院整体解决方案应用超500家等级医院；面向个人用户的健康助手"讯飞 晓 ...